A vertebrate review found lifespan extension with dietary restriction and rapamycin
Metformin lacked statistically supported lifespan extension in this analysis. Differences among studies and publication bias complicate the findings.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
Across vertebrate studies, dietary restriction and rapamycin showed statistically supported lifespan extension, while metformin did not. The authors described rapamycin and dietary restriction findings as comparable. However, substantial differences among studies, publication bias and sensitivity to lifespan reporting limit that interpretation. This abstract does not establish a lifespan benefit for people.
The abstract provides no numerical lifespan gains or precise between-treatment comparison. It reports substantial study variation and publication bias, so the apparent similarity cannot establish equivalence.
The endpoint was lifespan
The review examined how long vertebrates lived, comparing dietary restriction findings with drug findings. It did not report a human treatment result, and the abstract does not identify the species contributing to each intervention's evidence.
Why reporting matters
Results changed depending on how lifespan was summarized. Different statistical-significance findings also do not establish that rapamycin outperformed metformin. The authors found no consistent sex-related pattern across the treatments and reporting measures.
The original publication
Rapamycin, Not Metformin, Mirrors Dietary Restriction-Driven Lifespan Extension in Vertebrates: A Meta-Analysis.
Ivimey-Cook ER, Sultanova Z, Maklakov AA
Aging Cell · 2025
- PubMed ID
- 40532901
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.